- 1 Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2
- 2 Infection
- 3 Apurv Soni MD, PhD^{1,2,3}, Carly Herbert BA¹, Honghuang Lin PhD^{1,2}, Yi Yan PhD⁴, Caitlin Pretz
- 4 MS¹, Pamela Stamegna MD¹, Biqi Wang PhD^{1,2}, Taylor Orwig BS¹, Colton Wright MS¹, Seanan
- 5 Tarrant BS¹, Stephanie Behar BA¹, Thejas Suvarna BBA, BS⁵, Summer Schrader BA⁵, Emma
- 6 Harman MPH⁵, Chris Nowak BA⁵, Vik Kheterpal MD⁵, Lokinendi V Rao PhD⁶, Lisa Cashman
- 7 MPH⁶, Elizabeth Orvek MS³, Didem Ayturk MS³, Laura Gibson MD⁷, Adrian Zai, MD PhD³,
- 8 Steven Wong BA³, Peter Lazar BS³, Ziyue Wang MPH⁸, Andreas Filippaios¹, Bruce Barton
- 9 PhD³, Chad J. Achenbach MD, MPH⁹, Robert L. Murphy MD⁹, Matthew Robinson MD¹⁰, Yukari
- 10 C. Manabe MD¹⁰, Shishir Pandey BE¹, Andres Colubri PhD¹¹, Laurel O'Connor MD¹², Stephenie
- 11 C. Lemon PhD³, Nisha Fahey DO, ScM^{1,3,13}, Katherine L Luzuriaga MD^{14,15}, Nathaniel Hafer
- 12 PhD^{14,15}, Kristian Roth PhD⁴, Toby Lowe⁴, Timothy Stenzel MD PhD¹⁶, William Heetderks PhD¹⁷,
- 13 John Broach MD, MPH, MBA¹², David D McManus MD, ScM^{1,2,8}
- 14 Affiliations:
- ¹⁵ ¹Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan
- 16 Medical School, Worcester, MA, USA
- ²Division of Health System Science, Department of Medicine, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ³Department of Population and Quantitative Health Sciences, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ⁴ OHT7 Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US
 Food and Drug Administration, Silver Spring, Maryland
- 23 ⁵CareEvolution, LLC, Ann Arbor, MI, USA
- ⁶Quest Diagnostics, Marlborough, MA, USA
- ⁷Division of Infectious Disease, Department of Medicine, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ⁸Division of Cardiology, Department of Medicine, University of Massachusetts Chan Medical
 School, Worcester, MA, USA
- ⁹Division of Infectious Disease, Department of Medicine, Havey Institute for Global Health,
 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
- ¹⁰Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of
 Medicine, Baltimore, MD, USA
- ¹¹Department of Microbiology and Physiological Systems, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ¹²Department of Emergency Medicine, University of Massachusetts Chan Medical School,
- 36 Worcester, MA, USA
- ¹³Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, MA,
 USA

- ¹⁴University of Massachusetts Center for Clinical and Translational Science, University of
- 40 Massachusetts Chan Medical School, Worcester, MA, USA
- ¹⁵Program in Molecular Medicine, University of Massachusetts Chan Medical School,
- 42 Worcester, MA, USA
- ¹⁶ Division of Microbiology, OHT7 Office of Product Evaluation and Quality, Center for Devices and
 Radiological Health, US Food and Drug Administration, Silver Spring, Maryland
- ¹⁷National Institute of Biomedical Imaging and Bioengineering, NIH, via contract with Kelly
 Services, Bethesda, MD, USA
- 47 Corresponding Author:
- 48 Apurv Soni, MD PhD
- 49 Assistant Professor, Program in Digital Medicine
- 50 Department of Medicine
- 51 UMass Chan Medical School
- 52 Worcester, MA
- 53 01605
- 54
- 55

56 Abstract

- 57 **Background:** Performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) varies over the
- course of an infection, and their performance in screening for SARS-CoV-2 is not well
- 59 established. We aimed to evaluate performance of Ag-RDT for detection of SARS-CoV-2 for
- 60 symptomatic and asymptomatic participants.
- 61 **Methods:** Participants >2 years old across the United States enrolled in the study between
- 62 October 2021 and February 2022. Participants completed Ag-RDT and molecular testing (RT-
- 63 PCR) for SARS-CoV-2 every 48 hours for 15 days. This analysis was limited to participants who
- 64 were asymptomatic and tested negative on their first day of study participation. Onset of
- 65 infection was defined as the day of first positive RT-PCR result. Sensitivity of Ag-RDT was
- 66 measured based on testing once, twice (after 48-hours), and thrice (after 96 hours). Analysis
- 67 was repeated for different Days Post Index PCR Positivity (DPIPP) and stratified based on
- 68 symptom-status.
- 69 **Results**: In total, 5,609 of 7,361 participants were eligible for this analysis. Among 154
- participants who tested positive for SARS-CoV-2, 97 were asymptomatic and 57 had symptoms
- at infection onset. Serial testing with Ag-RDT twice 48-hours apart resulted in an aggregated
- sensitivity of 93.4% (95% CI: 89.1-96.1%) among symptomatic participants on DPIPP 0-6.
- 73 Excluding singleton positives, aggregated sensitivity on DPIPP 0-6 for two-time serial-testing
- among asymptomatic participants was lower at 62.7% (54.7-70.0%) but improved to 79.0%
- 75 (71.0-85.3%) with testing three times at 48-hour intervals.
- Discussion: Performance of Ag-RDT was optimized when asymptomatic participants tested
 three-times at 48-hour intervals and when symptomatic participants tested two-times separated
- 78 by 48-hours.
- 79

- 81
- 82

83 Introduction

84 SARS-CoV-2 diagnostic testing remains a cornerstone in our nation's fight against COVID-19, 85 and at-home rapid antigen tests (Ag-RDTs), while not perfect, provide a fast and convenient testing option. This type of test is available without a prescription (i.e., over-the-counter [OTC]), 86 87 easy-to-use, widely available, and, in some cases, preferred by the population over molecular 88 assays that require appointments, waiting in-line at testing centers, and waiting 24-48 hours for results.^{1–3} Despite their popularity, key gaps remain in our understanding of these tests, notably 89 90 their performance as a screening tool among asymptomatic people. Reports on Ag-RDT 91 performance among individuals testing while they are asymptomatic have been highly varied, ranging from sensitivities of 35.8% to 71% in cross-sectional screening evaluations.^{4,5} However, 92 performance has typically been evaluated based on the single use of Ag-RDTs, and few studies 93 94 have evaluated serial testing performance of Ag-RDTs among asymptomatic individuals. 95 Furthermore, United States Food and Drug Administration (FDA) emergency use authorization (EUA) of OTC antigen tests required a post-authorization demonstration of Ag-RDT 96 97 performance in a population with asymptomatic infection using serial testing. This manuscript describes primary findings from a large study designed in coordination with the National 98 99 Institutes of Health (NIH), Food and Drug Administration (FDA), and three major rapid antigen 100 test manufacturers to evaluate the performance of serial testing using rapid antigen tests for 101 detection of SARS-CoV-2 among asymptomatic individuals within the first week of infection. A 102 primary goal of this study was to provide broadly applicable data that could be leveraged to 103 satisfy the post-authorization requirement for all authorized OTC antigen tests.

104 Methods

Study Population and Design: Between October 18, 2021 and January 31, 2022, this 15-day
 prospective cohort study enrolled participants over the age of two years from across the country
 through a novel digital site-less study protocol. Details of the study design and protocol are

described elsewhere.⁶ This study was approved by WIRB-Copernicus Group (WCG) Institutional 108 109 Review Board (20214875). In brief, participants were eligible to enroll through a smartphone 110 app if they did not have a SARS-CoV-2 infection in the prior three months, were without any 111 symptoms in the 14 days prior to enrollment and were able to drop-off prepaid envelopes with nasal swab samples at their local FedEx drop-off location. Enrolled participants were assigned 112 113 to one of three types of EUA Aq-RDT (Quidel QuickVue At-Home OTC COVID-19 Test, 114 BinaxNow COVID-19 Antigen Self-Test, or BD Veritor At-Home COVID-19 Test) and received a 115 home delivery of 10 Ag-RDTs and 7 home collection kits for reverse transcriptase polymerase chain reaction (RT-PCR) samples. Participants were asked to perform two self-collected 116 bilateral anterior nasal swab collections and paired testing (Ag-RDT (at home) and RT-PCR 117 (mailed to central lab)) between study day 1 and study day 13 on 48 hour intervals, with an 118 119 additional end-of-study bilateral anterior nasal swab collection for home Ag-RDT on study day 120 15. Two FDA-authorized, high sensitivity RT-PCR assays were performed on each nasal swab sample received at the central lab, and an additional tiebreaker assay was performed if the two 121 RT-PCR assays were discordant. 122

Measures: Aq-RDT results were based on self-reporting (Quidel QuickVue At-Home OTC 123 124 COVID-19 Test, BinaxNow COVID-19 Antigen Self-Test) or an automatic reader (BD Veritor At-125 Home COVID-19 Test), as per EUA instructions for use. Molecular comparator RT-PCR results were based on a combination of molecular test results for detection of SARS-Cov-2 infection 126 127 (Table S1), and onset of infection was defined as the day on which the molecular comparator 128 result was positive for the first time. Cycle threshold (Ct) values for the E-gene from one RT-PCR test were used as a measure to quantify viral load. To approximate performance of Ag-129 RDT if a person starts testing on different days from onset of infection, we identified Days Past 130 131 Index PCR Positivity (DPIPP) as different strata, for which, performance was calculated. 132 Symptomatic or asymptomatic classification was based on presence or absence of symptoms

133 on DPIPP for which the performance is calculated. Therefore, an individual who was

asymptomatic on DPIPP 0 may become symptomatic on DPIPP 2 and vice-versa.

135 Statistical Analysis: Participants were eligible for inclusion in this analysis if they did not report any symptoms and had negative SARS-CoV-2 molecular and Ag-RDT tests on study day 1. Our 136 137 decision to pool performance across the different tests was based on: 1) findings not shown in 138 this report that suggested the sensitivity of different Ag-RDT was similar to each other as a function of the viral load; and 2) the study was not designed to evaluate differences in 139 140 performance between the three different types of Ag-RDTs. Performance was calculated using 141 sensitivity (rapid antigen positivity/comparator positivity) for single-day testing, two-times serial 142 testing at 48-hour intervals, and three-times serial testing at 48-hour intervals for symptomatic and asymptomatic individuals based on day and patterns of positivity, as described in Table 1. 143 144 Calculations for sensitivity were repeated with testing starting on different DPIPP. Confidence 145 intervals for one-week sensitivity were estimated using the bootstrapping technique.⁷ Negative 146 Percent Agreement was calculated as a proportion of paired tests (Ag-RDT and molecular tests 147 performed on the same-day) based on the following formula: True Negative/[False Positive + True Negative], where True Negative refers to instances a negative molecular test was paired 148 149 with a negative Ag-RDT on the same day and False-Positive refers to a negative molecular test 150 paired with a positive Aq-RDT test. To evaluate the viral dynamics during infection, a mixed 151 effects logistic regression model was used to predict the probability of Ag-RDT positivity based 152 on Ct value and symptom status. Ct values, symptom status, rapid antigen testing series (one 153 test, two-tests, or three-tests), and their three-way interactions were fixed effects, while 154 participants' IDs was included as a random effect. Additionally, we used the Cochran-Armitage 155 test for trend to evaluate the associations between symptoms and Ct value categories (i.e., <20, 156 20-24.99, 25-29.99, 30-34.99, or 35+) among individuals who tested positive on a single rapid 157 antigen test, two consecutive tests, and three consecutive tests, respectively. We used

Bonferroni corrections (0.05/3=0.017) to adjust for multiple comparisons. All analyses were
 performed using R 4.1.1.⁸

160 **Results**

161 A total of 7,361 participants enrolled in the study, and 5,353 were eligible for this analysis. Of

the participants eligible for analysis, 154 individuals tested RT-PCR positive for SARS-CoV-2

during the study based on a composite definition described in Table S1; 97 were without

symptoms and 57 had symptoms at infection onset (Figure 1). Among the 5,199 participants

165 who did not test positive, there were 32,998 days of paired Ag-RDT and RT-PCR testing, where

166 comparator result was negative. Among these, 32,862 days had a concordant Ag-RDT negative

result, yielding a negative percent agreement of 99.6% (95% CI: 99.5-99.7%).

168 Performance of Ag-RDT to detect SARS-CoV-2 on day of infection onset (DPIPP: 0) was higher

among symptomatic participants (59.6%, 46.7-71.4%) in comparison to asymptomatic

participants (9.3%, 5.0-16.7%) (Figure 2; Table S2). Serial-testing with two Ag-RDT tests 48-

171 hours apart (Symptomatic: 92.2%, 81.5-96.9%; Asymptomatic: 39.3%, 29.8-49.7%) and three

172 Ag-RDT tests 48-hours apart (Symptomatic: 93.6%, 82.8-97.8%; Asymptomatic: 56.4%, 45.4-

173 66.9%) improved performance of Ag-RDT.

174 Notably, we observed that twenty participants had a singleton RT-PCR+, defined as a positive

test preceded and followed by a negative RT-PCR test within 48-54 hours. Of those with

singleton RT-PCR+ tests, none tested positive on Ag-RDT, only one had symptoms on the day

177 of the singleton positive test, and average Ct value was >35 (Figure S1). Excluding these

178 participants did not impact sensitivity of Ag-RDT among symptomatic participants, but improved

asymptomatic sensitivity to 11.7%, 50.7%, and 74.6% based on testing one, two, or three times

180 with Ag-RDT at 48-hour intervals, respectively, beginning on DPIPP 0.

181 To approximate real-world scenarios, where a person may not necessarily start testing with Ag-RDT on the day of infection onset, we calculated performance separately on DPIPP 2, 4, 6, 8, 182 183 and 10 (Figure 2; Table S2) to approximate scenarios where a person started serially testing 184 with Aq-RDTs on those days. Aggregated performance of Aq-RDT for DPIPP 0-6 among all 185 participants who were symptomatic on a given DPIPP was 82.5% (78.3-86.3%) for single-186 timepoint testing but with a range of sensitivity (calculated on a per DPIPP day basis) from 59.6 187 to 94.8%. Serial-testing using two-time testing improved sensitivity to 93.4% (90.4-95.9%) and 188 94.3% (91.4-97.0%) for three-time testing. Sensitivity of performing single test, two-test serial 189 testing, and three-test serial testing for asymptomatic people was 34.4% (28.8-39.8%), 55.3% (48.2-61.6%), 68.5% (61.0-75.7%), respectively during the first week of infection (DPIPP 0-6). 190 Excluding singleton RT-PCR positive, the first-week (DPIPP 0-6) sensitivity for asymptomatic 191 192 individuals was 38.8% (32.7-45.2-%), 62.7% (57.0-70.5%), 79.0% (70.1-87.4%), respectively for 193 testing one, two, or three times with Ag-RDT at 48-hour intervals.

194 Performance of Aq-RDT among symptomatic and asymptomatic participants was evaluated by 195 Ct value to analyze the performance by viral load. The distribution of Ct values significantly differed between symptomatic and asymptomatic participants, with symptomatic participants 196 197 having lower Ct values on average than asymptomatic participants at DPIPP 0 and 2 (p<0.001) 198 (Figure 3). On the day of index PCR positivity, more than 75% of asymptomatic individuals had 199 a Ct value 30 or higher, whereas less than 33% of symptomatic individuals had a Ct value 30 or 200 higher. At the end of 1-week from index PCR positivity (DPIPP 6), the majority of both 201 asymptomatic and symptomatic individuals had a Ct value less than 30. Figure 4 demonstrates 202 the sensitivity of Ag-RDT for different Ct values based on postestimation results from a 203 multilevel model. The sensitivity was lowest among asymptomatic participants who performed a 204 single test for all Ct values > 20, compared to symptomatic participants who performed a single 205 test and symptomatic and asymptomatic participants who performed two-test and three-test

serial testing (Figure 4; Table S3). Two-test serial testing among symptomatic individuals and
 three-times serial testing among both asymptomatic individuals and symptomatic individuals
 demonstrated sensitivity above 80% for Ct values < 32.

209 Discussion

210 We report findings from the largest study to date of paired Ag-RDT and RT-PCR testing for a 211 comparative performance evaluation of Ag-RDTs among people with and without symptoms. 212 These results provide compelling reasons to suggest that frequency of Ag-RDT testing should 213 be adjusted to include additional repeat testing. These data suggest an improvement in test 214 performance when symptomatic individuals test two times 48-hours apart using Ag-RDTs. 215 Likewise, there are notable performance improvements in asymptomatic individuals when an 216 initial Ag-RDT test was followed by at least 2 subsequent tests at 48-hour intervals. These 217 results should be considered in the context of our study protocol which indicated testing at 48-218 hour intervals, and thus these data cannot support conclusions about serial testing for time 219 intervals shorter than 48-hours.

220 These findings represent a comprehensive evaluation of the time dependent performance of Ag-RDT tests among the intended use population (i.e., symptomatic and asymptomatic individuals) 221 222 throughout the course of molecular test positivity. Restricting findings from our study to match 223 observation windows from previous studies, we found similar sensitivity as found in previous studies for asymptomatic and symptomatic participants for a single-time test.⁹ Unlike previous 224 225 reports, which used composite sampling methods and lacked sufficient longitudinal data to 226 adequately evaluate performance of Ag-RDT from the onset of infection, we were able to approximate performance of Ag-RDT for symptomatic and asymptomatic users by comparing 227 228 performance within the first week of infection, to align with the indications listed in the EUA, and to evaluate the performance of serial testing within this paradigm.^{10,11} 229

We observed that more than one in ten new infections were singleton-positive, which escaped detection by rapid antigen tests. Evaluation of Ct values of these singleton-positive revealed that all of them had Ct value > 30 and average Ct count was 35. The finding of singleton RT-PCR positive testing needs to be further investigated to understand the clinical significance of this observation.

235 Our finding of higher Ct value associated with lower sensitivity is in line with results from a comprehensive meta-analysis encompassing data from 214 clinical studies and 112,323 236 237 samples, which demonstrated that sensitivity of rapid antigen testing deteriorated with increasing Ct values.⁹ We also observed that rapid antigen tests have higher sensitivity among 238 239 symptomatic participants, regardless of Ct value. The finding that performance of rapid antigen 240 tests differed with respect to Ct values between symptomatic and asymptomatic participants 241 was unexpected, as rapid antigen test performance has often been considered to be a function of viral load.^{12,13} However, this may suggest that the difference in performance between 242 243 asymptomatic and symptomatic participants is more than just a function of viral dynamics. It is 244 possible that symptomatic and asymptomatic individuals differ in three other domains: 1) interpretation of results; 2) administration of tests; 3) physiology (i.e., amount of secretions 245 246 available for sampling). Previous work found that symptom status was not a predictor of false negative results; however, self-interpretation of results may introduce bias.¹⁴ These three 247 248 hypotheses are subject to further inquiry, as it is important to determine the role of these factors 249 in rapid antigen test performance. Additionally, a previous report suggested that certain 250 haplotypes of the human leukocyte antigen (HLA) loci are two to eight-fold more likely to 251 experience an asymptomatic infection, and in a large GWAS study, this haplotype was found to be prevalent in roughly 10% of the patients.¹⁵ Similar observations have been made with Human 252 253 Immunodeficiency Virus, where certain genotypes are associated with lower propensity of 254 infection. The impact of HLA haplotype on COVID-19 infections should be investigated further.

255 This study does have limitations. This study was conducted during the circulation of the Delta and Omicron SARS-CoV-2 variants, and future variants may warrant further investigation, 256 especially as milder, less symptomatic variants emerge.^{16,17} Additionally, specimens were self-257 258 collected for RT-PCR and Ag-RDTs were self-performed. However, data has consistently shown 259 substantial agreement between self-collected and clinician-collected anterior nasal swabs for SARS-CoV-2 testing.^{18,19} Further, this primary analysis does not account for differences in 260 261 severity or type of symptoms. Public health implications of our findings suggest that people 262 testing for SARS-CoV-2 should exercise caution despite an initial negative rapid antigen-test and favor mask-wearing and avoiding crowded places if they suspect they may be infected or 263 264 have been exposed. Additionally, the rates of false positive results in the study were low: 265 therefore, any Aq-RDT positive result should be considered positive without the need to retest. 266 Further, in the context of reports of viral culture positivity more than five days after initial positive 267 test, our findings support isolation for a longer period of time to prevent the potential of spread of SARS-CoV-2 to others.²⁰ Further research is needed to quantitatively estimate the benefits of 268 269 Ag-RDT for early detection of infection and initiation of treatment, especially in settings where 270 access to molecular testing is limited or molecular test results are delayed. Dissemination of clear guidance for appropriate testing using Ag-RDT based on data from this study may help 271 272 preserve confidence in the performance of serial Aq-RDT to detect SARS-CoV-2 virus, 273 especially as reports of individual false negative Ag-RDT from inadequate serial testing, contrary to the tests' intended usage and guidance from the FDA, proliferate in lay media. 274

275

276 Competing Interest Statement: DDM reports consulting and research grants from Bristol-Myers Squibb and Pfizer, consulting and research support from Fitbit, consulting and research support 277 278 from Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial research support from Apple Computer, consulting/other support from Heart Rhythm Society. 279 280 YCM has received research grant support to Johns Hopkins University from Hologic, Cepheid, Roche, ChemBio, Becton Dickinson, miDiagnostics, and has provided consultative support to 281 282 Abbott..

- 283 Funding Statement: This study was funded by the NIH RADx Tech program under
- 284 3U54HL143541-02S2 and NIH CTSA grant UL1TR001453. The views expressed in this
- manuscript are those of the authors and do not necessarily represent the views of the National 285
- Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood 286
- 287 Institute; the National Institutes of Health, or the U.S. Department of Health and Human
- Services. Salary support from the National Institutes of Health U54HL143541, R01HL141434, 288
- 289 R01HL137794, R61HL158541, R01HL137734, U01HL146382 (AS, DDM), U54EB007958-13
- 290 (YCM, MLR), AI272201400007C, UM1AI068613 (YCM), U54EB027049 and U54EB027049-
- 291 02S1 (CJA, RLM).

Acknowledgment: We are grateful to our study participants and to our collaborators from the 292 293 National Institute of Health (NIBIB and NHLBI) who provided scientific input into the design of 294 this study and interpretation of our results but could not formally join as co-authors due to 295 institutional policies and to the Food and Drug Administration (Office of In Vitro Diagnostics and 296 Radiological Health) for their involvement in the primary TUAH study. We received meaningful 297 contributions from Drs. Bruce Tromberg, Jill Heemskerk, Dennis Buxton, Felicia Qashu, Erin 298 Iturriaga, Jue Chen, Andrew Weitz, and Krishna Juluru. We are greatly appreciative of the 299 contribution to this study by the numerous staff at UMass Chan, including critical support from 300 Karen Gilliam, Mary Janet McCarthy, Amber Showers, Cynthia Kinahan, Kimberly Cantin, and 301 Danielle Howard. We would also like to acknowledge the support provided by clinical 302 coordinators from Threewire, Inc. We are thankful to county health departments across the country who helped with recruitment for this study by spreading the word in their networks. 303

304 **References**

305 306 307	1.	Ricks S, Kendall EA, Dowdy DW, Sacks JA, Schumacher SG, Arinaminpathy N. Quantify the potential value of antigen-detection rapid diagnostic tests for COVID-19: a model analysis. <i>BMC Med</i> . 2021;19(1):75. doi:10.1186/s12916-021-01948-z		
308 309 310 311	2.	Møller IJB, Utke AR, Rysgaard UK, Østergaard LJ, Jespersen S. Diagnostic performance, user acceptability, and safety of unsupervised SARS-CoV-2 rapid antigen-detecting tests performed at home. <i>International Journal of Infectious Diseases</i> . 2022;116:358-364. doi:10.1016/J.IJID.2022.01.019		
312 313 314	3.	Peeling RW, Olliaro PL, Boeras Dl, Fongwen N. Scaling up COVID-19 rapid antigen test promises and challenges. <i>Lancet Infect Dis</i> . 2021;21(9):e290-e295. doi:10.1016/S147 3099(21)00048-7		
315 316 317 318	4.	Siddiqui ZK, Mihir C, Robinson ML, et al. Implementation and Accuracy of BinaxNOV Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a H Volume Self-Referred Testing Site. <i>Microbiol Spectr</i> . 2021;9(3):e01008-21. doi:10.1128/Spectrum.01008-21		
319 320 321 322	5.	Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020. <i>Morbidity and Mortality Weekly Report</i> . 2021;70(3):100. doi:10.15585/MMWR.MM7003E3		
323 324 325 326	6.	Soni A, Herbert C, Pretz C, Stamegna P, Filippaios A. Finding a Needle in the Haystack: Design and Implementation of a Digital Site-less Clinical Study of Serial Rapid Antigen Testing to Identify Asymptomatic SARS-CoV-2 Infection. <i>medRxiv</i> . Published online Augu 8, 2022.		
327 328	7.	Davison AC, Hinkley D v. <i>Bootstrap Methods and Their Application</i> . Cambridge University Press; 1997. doi:DOI: 10.1017/CBO9780511802843		
329 330	8.	R Development Core Team. R: A language and environment for statistical computing. Published online 2022.		
331 332 333	9.	Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. <i>PLoS Med.</i> 2021;18(8):e1003735 https://doi.org/10.1371/journal.pmed.1003735		
334 335 336 337 338	10.	Winnett AV, Akana R, Shelby N, et al. Extreme differences in SARS-CoV-2 Omicron viral loads among specimen types drives poor performance of nasal rapid antigen tests for detecting presumably pre-infectious and infectious individuals, predicting improved performance of combination specimen antigen tests. <i>medRxiv</i> . Published online January 2022:2022.07.13.22277513. doi:10.1101/2022.07.13.22277513		
339 340 341	11.	Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With I PCR and Viral Culture During the Course of SARS-CoV-2 Infection. <i>JAMA Intern Med</i> . 2022;182(7):701-709. doi:10.1001/jamainternmed.2022.1827		

342 343 344 345	12.	Routsias JG, Mavrouli M, Tsoplou P, Dioikitopoulou K, Tsakris A. Diagnostic performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in monitoring the infectiousness of COVID-19 patients. <i>Scientific Reports</i> /. 123AD;11:22863. doi:10.1038/s41598-021-02197-z	
346 347	13.	Mak GC, Cheng PK, Lau SS, et al. Evaluation of rapid antigen test for detection of SARS- CoV-2 virus. <i>Journal of Clinical Virology</i> . 2020;129. doi:10.1016/J.JCV.2020.104500	
348 349 350	14.	Stohr JJJM, Zwart VF, Goderski G, et al. Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests for people with suspected COVID-19 in the community. <i>Clinical Microbiology and Infection</i> . 2022;28(5):695-700. doi:10.1016/J.CMI.2021.07.039	
351 352 353	15.	Augusto DG, Yusufali T, Peyser ND, et al. HLA-B*15:01 is associated with asymptomat SARS-CoV-2 infection. <i>medRxiv</i> . Published online September 10, 2021:2021.05.13.21257065. doi:10.1101/2021.05.13.21257065	
354 355 356	16.	Soni A, Herbert C, Filippaios A, et al. Comparison of Rapid Antigen Tests' Performance Between Delta and Omicron Variants of SARS-CoV-2. <i>Ann Intern Med</i> . Published online October 11, 2022. doi:10.7326/M22-0760	
357 358 359	17.	Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduct Target Ther</i> . 2022;7(1):141. doi:10.1038/s41392-022-00997-x	
360 361 362 363	18.	McCulloch DJ, Kim AE, Wilcox NC, et al. Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS- CoV-2 Infection. <i>JAMA Netw Open</i> . 2020;3(7):e2016382-e2016382. doi:10.1001/jamanetworkopen.2020.16382	
364 365 366 367	19.	Lindner AK, Nikolai O, Kausch F, et al. Head-to-head comparison of SARS-CoV-2 antigen- detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. <i>European Respiratory Journal</i> . 2021;57(4):2003961. doi:10.1183/13993003.03961-2020	
368 369 370	20.	Boucau J, Marino C, Regan J, et al. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection. <i>New England Journal of Medicine</i> . 2022;387(3):275-277. doi:10.1056/NEJMc2202092	
371			
372			
373			

374 Tables and Figures

375 Table 1: Matrix for Calculation of Sensitivity of Rapid Antigen Tests for Detection of

Days Past Index PCR Positivity – DPIPP (strata)	Denominator for Sensitivity: PCR Positive on following DPIPP	Numerator for Sensitivity: At least one positive rapid antigen test on one of the following DPIPP (Other days could not be missing, invalid, or uninterpreted)						
		Single test	2-test serial testing	3-test serial testing				
0	0	0	0, 2	0, 2, 4				
2	0 and 2	2	2, 4	2, 4, 6				
4	0 and 4	4	4, 6	4, 6, 8				
6	0 and 6	6	6, 8	6, 8, 10				
8	0 and 8	8	8, 10	8, 10, 12				
10	0 and 10	10	10, 12	NA				
Classification of symptomatic vs asymptomatic based on symptom self-report on DPIPP								

376

5 SARS-CoV-2 Virus in Relation to Days Past Index PCR Positivity (DPIPP)

377

379

Figure 1: CONSORT Diagram for Test Us At Home Study to Calculate Performance of Rapid Antigen Tests for Detection of SARS-CoV-2 Virus



380

381 Legend:

7,361 total participants were enrolled in the study, and 154 participants were eligible for the analysis and tested positive for SARS-CoV-2 by RT-PCR during the study period. Of these participants, 97 were asymptomatic and 57 were symptomatic on day of index comparator positive result. a= participants replaced their assigned rapid antigen tests with commercially obtained rapid antigen tests; b= dates of RT-PCR testing could not be verified based on triangulation of self-reported, shipping, and resulting data.

388

Figure 2: Performance of Rapid Antigen Tests for Detection of SARS-CoV-2 Virus in Relation to First Day of Molecular Positivity



392

Legend: Performance was calculated using sensitivity (rapid antigen positivity/comparator 393 394 positivity) for single-day testing, two-times serial testing at 48-hour intervals, and threetimes serial testing at 48-hour intervals for symptomatic and asymptomatic individuals 395 based on day and patterns of positivity. Calculations for sensitivity were repeated with 396 397 testing starting on different DPIPP. Error bars represent 95% Confidence Intervals. Performance of Ag-RDT to detect SARS-CoV-2 on day of infection onset was higher 398 399 among symptomatic participants (59.6%) compared to asymptomatic participants (9.3%). Serial-testing with two Ag-RDT tests 48-hours apart and three Ag-RDT tests 48-hours apart 400 improved performance of Ag-RDT within the first week of SARS-CoV-2 infection. Excluding 401 402 participants with singleton RT-PCR+ results improved sensitivity of Ag-RDT among asymptomatic participants to 11.7%, 50.7%, and 74.6% based on testing one, two, or three 403 404 times with Ag-RDT at 48-hour intervals, respectively, beginning on DPIPP 0.



406 Figure 3: Cycle Threshold values by Day Post Index PCR-Positivity by Symptom Status

407

408Legend: Error bars represent 95% Confidence Intervals. Symptomatic participants who409tested positive by RT-PCR had significantly lower Cycle threshold (Ct) values on average410than asymptomatic participants at DPIPP 0 and 2. On DPIPP 0, >75% of asymptomatic411individuals had a Ct value \geq 30, whereas <33% of symptomatic individuals had a Ct value</td>412 \geq 30. Symptomatic participants had a lower proportion of individuals with CT values \geq 30 at413all DPIPP. DPIPP: Day post index PCR-positive.

Figure 4: Predicted Probability of Rapid Antigen Test Positivity by Symptom Status and Serial Testing Schedule



417



419 positivity based on Ct value and symptom status. Error bars represent 95% Confidence

420 Intervals. The sensitivity was lowest among asymptomatic participants who performed a single

test for all Ct values > 20. Two-test serial testing among symptomatic individuals and three-

times serial testing among both asymptomatic individuals and symptomatic individuals

demonstrated sensitivity above 80% for Ct values < 32.